Wellstar International Inc., through its wholly-owned subsidiary, Trillennium Medical Imaging, develops and licenses the use of advanced thermal imaging technology in consumer health care markets worldwide. The company’s TMI infrared technology and software is approved by the United States Food and Drug Administration (FDA) as an adjunctive diagnostic screening procedure for early breast cancer detection, orthopedic applications, pain dysfunctions, deep tissue injuries and detection of pressure ulcers.
The company announced today that it is achieving success in its beta test in a long-term acute care facility (LTAC). Wellstar has been imaging existing and newly admitted patients twice a week in one of its beta test long-term care facilities. The system is successfully tracking existing wounds as well as deep tissue injury that ultimately leads to a pressure ulcer.
Wellstar’s goal is to be able to detect a deep tissue injury and have the facility treat the injury so that it never becomes a pressure ulcer. To date, the Wellstar TMI Imaging System has been able to detect deep tissue injuries as well as other ulcers that would have gone otherwise unnoticed by the caregivers until the ulcer broke the skin.
The company’s TMI system becomes a very cost-effective tool because if an ulcer breaks the skin, the cost could average almost $40,000 to treat and close the sore. As Wellstar continues to see growing success in its beta trials, the company should be in a position to go to market with their product within the next 6-7 months.
Wellstar seeks to be the first-to-market in deep tissue injury and pressure ulcer detection using its proprietary infrared imaging system. The company believes that the initial emphasis on marketing their systems will be to the LTAC industry. There are over 700 of these facilities in the United States and their uses will correlate with the facilities that are or will be involved with the beta test. This should lead to over $1 million per month in revenue for Wellstar.